Recent research explores how preconception GLP-1RA use influences metabolic health during pregnancy. The study investigated the link between glucagon-like peptide-1 receptor agonists (GLP-1RAs) or tirzepatide and the risk of gestational diabetes mellitus (GDM). As these medications become more common for weight management, understanding their carry-over effects is vital for maternal care.

Impact of Preconception GLP-1RA Use on Gestational Diabetes Risk

The retrospective cohort study matched women based on their body mass index and metabolic markers. Interestingly, patients who discontinued treatment 6 to 18 months before pregnancy showed no significant increase in GDM risk. However, the study found a 53% higher risk of GDM among women who stopped the medication abruptly. Specifically, this occurred when discontinuation happened within 90 days of their pregnancy encounter. Consequently, this indicates that the timing of drug cessation significantly affects metabolic outcomes.

Moreover, the researchers noted a distinct weight rebound effect. Women who stopped the medication close to conception experienced a steeper increase in gestational BMI. This rapid weight gain likely drives the elevated risk of developing gestational diabetes. In contrast, those who discontinued therapy earlier had a more modest rebound. This gain did not increase GDM risk compared to matched controls.

Clinical Strategies for Managing Weight Rebound

These findings emphasize that clinicians must prioritize preconception care strategies. Because the benefit of preconception GLP-1RA use can be lost through rapid weight regain, monitoring weight velocity is critical. Additionally, physicians should counsel patients on the potential for metabolic rebound when stopping incretin-based therapies. This proactive approach helps preserve the metabolic benefits gained during treatment.

Furthermore, prospective studies are necessary to confirm these observations. Until then, these results serve as a guide for managing the post-withdrawal window in women receiving therapy for obesity. Effective management might involve more frequent weight monitoring and nutritional support immediately after discontinuation.

Frequently Asked Questions

Does taking GLP-1RAs before pregnancy increase the risk of gestational diabetes?

It depends on the timing of discontinuation. Discontinuing the medication long before conception does not appear to increase risk. However, stopping abruptly within 90 days of pregnancy is linked to a 53% higher risk of GDM.

Why does abrupt discontinuation of GLP-1RAs increase GDM risk?

Abrupt cessation often leads to a rapid metabolic rebound or steep weight gain. This excessive weight gain during gestation is the primary driver of the increased risk for gestational diabetes.

Should women stop GLP-1RAs before trying to conceive?

Yes, current guidelines recommend stopping these medications at least two months before conception due to potential fetal risks. Clinicians should help patients manage the subsequent weight rebound to ensure a healthy pregnancy.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Physicians should exercise their professional judgment and cross-reference multiple sources before making clinical decisions. Refer to the latest local and national guidelines for clinical practice.

References

Banerjee M et al. Pre-Pregnancy GLP-1 Receptor Agonist or Tirzepatide Use and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry-Over Versus Post-Discontinuation Metabolic Rebound in a Multinational Federated Cohort. Diabetes Obes Metab. 2026 May 07. doi: 10.1111/dom.70853. PMID: 42098901.

Maya J, et al. Prepregnancy GLP-1 receptor agonist use and gestational weight gain. JAMA. 2025;334(21):1982-1990.

Imbroane A, et al. Adverse obstetrical outcomes and history of GLP-1 receptor agonist use. American Journal of Obstetrics & Gynecology. 2025.